LEO Pharma Announces FDA Acceptance of Dersimelagon NDA with Priority Review and Closes Acquisition from Tanabe Pharma

LEO Pharma said the FDA accepted its New Drug Application for dersimelagon and granted Priority Review, accelerating the regulatory assessment timeline. The company also completed its acquisition of the asset from Tanabe Pharma; no financial terms or FDA decision date were disclosed in the article.